Frequency of Hprt mutant lymphocytes and micronucleated erythrocytes in p53-haplodeficient mice treated perinatally with AZT and AZT in combination with 3TC

Environmental and Molecular Mutagenesis

Volumn 48, Issue 3-4, 2007, Pages 270-282

  Dobrovolsky, Vasily N ^a,c   Shaddock, Joseph G ^a   Mittelstaedt, Roberta A ^a   Bishop, Michelle E ^a   Lewis, Sherry M ^a   Lee, Fei W ^a   Aidoo, Anane ^a   Leakey, Julian E A ^a   Dunnick, June K ^b   Heflich, Robert H ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c HFT 120 ^*  (United States)

Author keywords

Neonatal exposure; Normochromatic erythrocytes; Nucleoside analog reverse transcriptase inhibitors; Reticulocytes; Transplacental exposure

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MUTANT; CHEMICAL MUTAGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG CARCINOGENICITY; DRUG MIXTURE; ERYTHROCYTE COUNT; FEMALE; FETUS; GENE FREQUENCY; GENOTOXICITY; GESTATION PERIOD; HPRT GENE; KNOCKOUT MOUSE; LYMPHOCYTE; MALE; MICRONUCLEUS; MOUSE; NEWBORN; NONHUMAN; PERINATAL DRUG EXPOSURE; REPORTER GENE; RETICULOCYTE COUNT; SINGLE DRUG DOSE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANIMALS, NEWBORN; ANTI-HIV AGENTS; DRUG INTERACTIONS; FEMALE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LAMIVUDINE; LYMPHOCYTES; MALE; MATERNAL-FETAL EXCHANGE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MUTATION; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53; ZIDOVUDINE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MUS; RODENTIA;

EID: 34047239485     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20280     Document Type: Article

References (50)

1. Adams WT, Skopek TR. 1987. Statistical test for the comparison of samples from mutational spectra. J Mol Biol 194:391-396.
2. Ayers KM, Clive D, Tucker WE Jr, Hajian G, de Miranda P. 1996. Non-clinical toxicology studies with zidovudine: Genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol 32:148-158.
3. Bhana N, Ormrod D, Perry CM, Figgitt DP. 2002. Zidovudine: A review of its use in the management of vertically-acquired pediatric HIV infection. Paediatr Drugs 4:515-553.
4. Bialkowska A, Bialkowski K, Gerschenson M, Diwan BA, Jones AB, Olivero OA, Poirier MC, Anderson LM, Kasprzak KS, Sipowicz MA. 2000. Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido- 3′-deoxythymidine (AZT). Carcinogenesis 21:1059-1062.
5. Bienstock RJ, Copeland WC. 2004. Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase. Mitochondrion 4:203-213.
6. Cammack N, Rouse P, Marr CL, Reid PJ, Boehme RE, Coates JA, Penn CR, Cameron JM. 1992. Cellular metabolism of (-) enantiomeric 2′-deoxy- 3′-thiacytidine. Biochem Pharmacol 43:2059-2064.
7. Cariello NF. 1994. Software for the analysis of mutations at the human hprt gene. Mutat Res 312:173-185.
8. Chumakov PM. 2000. Function of the p53 gene: Choice between life and death. Biochemistry (Mosc) 65:28-40.
9. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331:1173-1180.
10. Copeland WC, Chen MS, Wang TS. 1992. Human DNA polymerases α and β able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem 267:21459-21464.
11. DeMarini DM, Brockman HE, de Serres FJ, Evans HH, Stankowski LF Jr, Hsie AW. 1989. Specific-locus mutations induced in eukaryotes (especially mammalian cells) by radiation and chemicals: A perspective. Mutat Res 220:11-29.
12. Dertinger SD, Chen Y, Miller RK, Brewer KJ, Smudzin T, Torous DK, Hall NE, Olvany KA, Murante FG, Tometsko CR. 2003. Micronucleated CD71-positive reticulocytes: A blood-based endpoint of cytogenetic damage in humans. Mutat Res 542:77-87.
13. Divi RL, Leonard SL, Kuo MM, Nagashima K, Thamire C, St Claire MC, Wade NA, Walker VE, Poirier MC. 2007. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen 48:201-209.
14. +/- mice: Automated scoring of lymphocyte clones using a fluorescent viability indicator. Environ Mol Mutagen 36:283-291.
15. /- mice. Mutat Res 570:227-235.
16. Dobrovolsky VN, Shaddock JG. Heflich RH. 2005b. Analysis of in vivo mutation in the hprt and tk genes of mouse lymphocytes. In: Keohavong P, Grant SG, editors. Molecular Toxicology Protocols. Totowa. NJ: Humana Press, pp 133-144.
17. French J, Storer RD, Donehower LA. 2001. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol 29 (Suppl):24-29.
18. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83:8333-8337.
19. Gray NM, Marr CL, Penn CR, Cameron JM, Bethell RC. 1995. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase γ. Biochem Pharmacol 50:1043-1051.
20. Gulezian D, Jacobson-Kram D, McCullough CB, Olson H, Recio L, Robinson D, Storer R, Tennant R, Ward JM, Neumann DA. 2000. Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment. Toxicol Pathol 28:482-499.
21. Heddle JA, Hite M, Kirkhart B, Mavournin K, MacGregor JT, Newell GW, Salamone MF. 1983. The induction of micronuclei as a measure of genotoxicity. A report of the US Environmental Protection Agency Gene-Tox Program. Mutat Res 123:61-118.
22. Hong HH, Dunnick J. Herbert R, Devereux TR, Kirn Y, Sills RC. 2007. Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT. Environ Mol Mutagen 48:299-306.
23. Inoue T, Cronkite EP, Hirabayashi Y, Bullis JE Jr, Mitsui H, Umemura T. 1997. Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia. Leukemia 11 (Suppl 3):123-127.
24. Jansen JG, de Groot AJ, van Teijlingen CM, Tales AD, Vrieling H, van Zeeland AA. 1996. Induction of hprt gene mutations in splenic T-lymphocytes from the rat exposed in vivo to DNA methylating agents is correlated with formation of O6-methylguanine in bone marrow and not in the spleen. Carcinogenesis 17:2183-2191.
25. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. 1999. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 36:41-66.
26. Kewn S, Veal GJ, Hoggard PG, Barry MG, Back DJ. 1997. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol 54:589-595.
27. Kushi A, Edamura K, Noguchi M, Akiyama K, Nishi Y, Sasai H. 1998. Generation of mutant mice with large chromosomal deletion by use of irradiated ES cells-Analysis of large deletion around hprt locus of ES cell. Mamm Genome 9:269-273.
28. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
29. MacGregor JT, Wehr CM, Henika PR, Shelby MD. 1990. The in vivo erythrocyte micronucleus test: Measurement at steady state increases assay efficiency and permits integration with toxicity studies. Fundam Appl Toxicol 14:513-522.
30. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, Lachassine E, Barret B, Chaix ML, Bongain A, Ciraru-Vigneron N, Crenn-Hebert C, Delfraissy JF, Rouzioux C. Mayaux MJ, Blanche S. 2001. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 285:2083-2093.
31. Meng Q, Grosovsky AJ, Shi X, Walker VE. 2000a. Mutagenicity and loss of heterozygosity at the APRT locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine. Mutagen 15:405-410.
32. Meng Q, Su T, Olivero OA, Poirier MC, Shi X, Ding X. Walker VE. 2000b. Relationships between DNA incorporation, mutant frequency, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine. Toxicol Sci 54:322-329.
33. Meng Q, Walker DM, Olivero OA, Shi X, Antiochos BB, Poirier MC, Walker VE. 2000c. Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA 97:12667-12671.
34. Mitsumori K, Onodera H, Shimo T, Yasuhara K, Takagi H, Koujitani T, Hirose M, Maruyama C, Wakana S. 2000. Rapid induction of uterine tumors with p53 point mutations in heterozygous p53-deficient CBA mice given a single intraperitoneal administration of N-ethyl-N-nitrosourea. Carcinogenesis 21:1039-1042.
35. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. 1985. 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82:7096-7100.
36. +/- mice treated as neonates with 3′-azido-3′- deoxythymidine (AZT). Mutat Res 547:63-69.
37. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. 1991. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 266:9032-9038.
38. O'Neill JP, Gundel RM, Trombley LM, Walker VE. 2001. HPRT mutant frequency and mutation spectrum in newborns with perinatal exposue to antiviral drugs. Environ Mol Mutagen 37 (Suppl 32):58. (Abstract).
39. Poirier MC, Olivero OA, Walker DM, Walker VE. 2004. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 199:151-161.
40. Pritchard JB, French JE, Davis BJ, Haseman JK. 2003. The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111:444-454.
41. Shaddock JG, Dobrovolsky VN, Mittelstaedt RA, Heflich RH, Parsons BL. 2006. Frequency and types of spontaneous Hprt lymphocyte mutations in Pms2-deficient mice. Mutat Res 595:69-79.
42. Shah MM, Li Y, Christensen RD. 1996. Effects of perinatal zidovudine on hematopoiesis: A comparison of effects on progenitors from human fetuses versus mothers. AIDS 10:1239-1247.
43. Soudeyns H, Yao XI, Gao Q, Belleau B, Kraus JL, Nguyen-Ba N, Spira B, Wainberg MA. 1991. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 35:1386-1390.
44. +/- hemizygous knockout mouse: Overview of available data. Toxicol Pathol 29 (Suppl):30-50.
45. Tennant RW, French JE, Spalding JW. 1995. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 103:942-950.
46. +/- mice treated neonatally with zidovudine and lamivudine. Carcinogenesis 23:1427-1432.
47. Von Tungeln LS, Williams LD, Doerge DR, Shaddock JG, McGarrity LJ, Morris SM, Mittelstaedt RA, Heflich RH, Beland FA. 2007. Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine. Environ Mol Mutagen 48:258-269.
48. Walker VE, Jones IM, Crippen TL, Meng Q, Walker DM, Bauer MJ, Reilly AA, Tates AD, Nakamura J, Upton PB, Skopek TR. 1999. Relationships between exposure, cell loss and proliferation, and manifestation of Hprt mutant T cells following treatment of preweanling, weanling, and adult male mice with N-ethyl-N-nitrosourea. Mutat Res 431:371-388.
49. Wang J, Chen T, Honma M, Chen L, Moore MM. 2007. 3′-azido-3′- deoxythymidine induces deletions in L5178Y mouse lymphoma cells. Environ Mol Mutagen 48:248-257.
50. Witt KL, Tice RR, Wolfe GW, Bishop JB. 2004. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3′-azido-3′-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage. II. Effects of the individual agents compared to combination treatment. Environ Mol Mutagen 44:321-328.